Array shares surge as second chapter of its PhIII cancer combo story ends on an upbeat note
Array Biopharma stock got a bounce out of the upbeat assessment of the second part of its Phase III study of binimetinib combined with encorafenib, demonstrating their ability to significantly improve progression free survival rates for patients with BRAF-mutant advanced melanoma. The top-line results lay the foundation for an NDA, the company adds, which is expected to be delivered to the FDA this summer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.